These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 27259906)

  • 21. Levels of Intracellular Phosphorylated Tenofovir and Emtricitabine Correlate With Natural Substrate Concentrations in Peripheral Blood Mononuclear Cells of Persons Prescribed Daily Oral Truvada for HIV Pre-exposure Prophylaxis.
    Haaland RE; Holder A; Pau CP; Swaims-Kohlmeier A; Dawson C; Smith DK; Segolodi TM; Thigpen MC; Paxton LA; Parsons TL; Hendrix CW; Hart CE
    J Acquir Immune Defic Syndr; 2017 Jul; 75(3):e86-e88. PubMed ID: 28225438
    [No Abstract]   [Full Text] [Related]  

  • 22. Truvada (emtricitabine/tenofovir) pre-exposure prophylaxis roll-out among South African university students: Lots of positives, but let us keep an eye on possible surprises.
    Montjane K; Dlamini S; Dandara C
    S Afr Med J; 2018 Feb; 108(2):79-81. PubMed ID: 29429434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Not Available].
    Nau JY
    Rev Med Suisse; 2016 Aug; 12(526):1346-1347. PubMed ID: 28671781
    [No Abstract]   [Full Text] [Related]  

  • 24. HOW DO I PAY FOR PrEP?
    Evans D
    Posit Aware; 2015; 27(5):18-9. PubMed ID: 26714339
    [No Abstract]   [Full Text] [Related]  

  • 25. MOVING FORWARD WITH PrEP. THE BASICS OF PrEP.
    Highleyman L
    Posit Aware; 2015; 27(5):2-3. PubMed ID: 26714333
    [No Abstract]   [Full Text] [Related]  

  • 26. Configuring the users of new HIV-prevention technologies: the case of HIV pre-exposure prophylaxis.
    Holt M
    Cult Health Sex; 2015; 17(4):428-39. PubMed ID: 25270549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Research. Approval of Gilead's Truvada for PrEP passes first hurdle at FDA.
    AIDS Policy Law; 2012 Jul; 27(8):1, 4. PubMed ID: 27024409
    [No Abstract]   [Full Text] [Related]  

  • 28. [Protection against HIV - but only with good compliance!].
    Oberhofer E
    MMW Fortschr Med; 2016 Jun; 158 Suppl 1():11. PubMed ID: 27259892
    [No Abstract]   [Full Text] [Related]  

  • 29. Hepatitis B virus reactivation or reinfection in a FEM-PrEP participant: a case report.
    Malahleha M; Ahmed K; Deese J; Nanda K; van Damme L; De Baetselier I; Burnett RJ
    J Med Case Rep; 2015 Sep; 9():207. PubMed ID: 26411737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.
    Kabbara WK; Ramadan WH
    J Infect Public Health; 2015; 8(5):409-17. PubMed ID: 26001757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tailoring biomedical interventions for key populations.
    Beyrer C
    Lancet HIV; 2015 Jan; 2(1):e8-9. PubMed ID: 26424235
    [No Abstract]   [Full Text] [Related]  

  • 32. Regulatory considerations for antiretroviral prophylaxis to prevent HIV acquisition.
    Miller V; Grant RM
    Clin Pharmacol Ther; 2014 Aug; 96(2):153-5. PubMed ID: 25056397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.
    Hey-Cunningham WJ; Murray JM; Natarajan V; Amin J; Moore CL; Emery S; Cooper DA; Zaunders J; Kelleher AD; Koelsch KK;
    AIDS; 2015 May; 29(8):911-9. PubMed ID: 25730509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.
    Valantin MA; Bittar R; de Truchis P; Bollens D; Slama L; Giral P; Bonnefont-Rousselot D; Pétour P; Aubron-Olivier C; Costagliola D; Katlama C;
    J Antimicrob Chemother; 2010 Mar; 65(3):556-61. PubMed ID: 20053692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Miscellaneous - profound coma, smoking and AIDS].
    Nau JY
    Rev Med Suisse; 2015 Nov; 11(495):2202-3. PubMed ID: 26742249
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.
    Porter DP; Toma J; Tan Y; Solberg O; Cai S; Kulkarni R; Andreatta K; Lie Y; Chuck SK; Palella F; Miller MD; White KL
    HIV Clin Trials; 2016 Feb; 17(1):29-37. PubMed ID: 26899540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preexposure prophylaxis: An emerging clinical approach to preventing HIV in high-risk adults.
    Blackwell CW
    Nurse Pract; 2014 Sep; 39(9):50-3. PubMed ID: 25140852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
    Vourvahis M; Davis J; Langdon G; Layton G; Fang J; Choo HW; Hansson AG; Tawadrous M
    Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?
    De Clercq E
    Med Res Rev; 2012 Jul; 32(4):765-85. PubMed ID: 22581627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
    Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T
    AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.